FTI GOVERNMENT AFFAIRS for PERRIGO, INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 18, 2019 | $30,000 | Replaced |
| 1st Quarter - Amendment | Oct 8, 2021 | $30,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Dextromethorphan, Pseudoephedrine restriction issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS CRAWFORD | — |
| DAVID PATRICK ROBERTSON | — |
Pharmacy PHA
Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines. FDA's proposed changes to generic drug labeling. "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018", H.R. 5333. "Over-the-Counter Drug Safety, Innovation, and Reform Act", S. 2315.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS CRAWFORD | — |
| SCOTT STYLES | — |
Taxation/Internal Revenue Code TAX
Monitor issues as they relate to the implementation of tax reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS CRAWFORD | — |
| DAVID PATRICK ROBERTSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.